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Summary The purpose of this paper is to describe temporal trends in the treatment of lung cancer in the
Merseyside Region of England over the years 1974-86. A detailed analysis of 9,090 cases of histologically
confirmed tumours showed that age at diagnosis and histological type were important prognostic factors, with
the 5 year survival of adenocarcinoma, squamous carcinoma, undifferentiated carcinoma and small cell
carcinoma after treatment being 22.5%, 18.5%, 10% and 3.5% respectively. An analysis of 741 cases of small
cell carcinoma given chemotherapy over the same period showed progressive improvement in 2 year survival
from 2.5 to 7.5% (P <0.001) and this was shown to be closely associated with the increasing use of
intravenous combination chemotherapy. The survival of patients who underwent surgical resection in the three
periods 1974-77, 1978-81 and 1982-86 showed a continuous improvement in median survival from 13 to 30
months (P <0.001). Overall survival curves of all treated cases showed a significant improvement in median
survival from 8 to 10 months and 5 year survival from 12.5 to 17.5% (P = 0.001). With improved staging
assessment, the value of surgical resection of all histological types is emphasised, and in the case of the small
cell subtype, the increasing use of combination chemotherapy would appear to have paralleled an increase in
median and 2 year survival. These data support the argument that with appropriate case selection, there is a
survival benefit associated with active treatment for lung cancer.
There are many hospital based studies of patients with lung
cancer: in general these are highly selected series and seldom
contain information on patients not given active treatment.
Population studies, on the other hand, while subject to varia-
tion in histological reporting, are free from problems of
selection of patients according to histological type, disease
extent, performance status and other determinants of out-
come (Capewell, 1987; Watkin, 1989).
The Mersey Region of the United Kingdom (population
2,423,400 (OPCS, 1985)) has a high incidence rate of lung
cancer (standardised registration ratio of 120 in 1984).
Related factors include a high proportion of social class IV
population, recognised to have a high cigarette consumption
and an association with exposure to asbestos in the ship-
building and dock industries. The Cancer Registration Ser-
vice, which includes central pathological review and linking
of death certification to Cancer Registry records, comprises a
large computerised data set associated with a high level of
case ascertainment from the population of one Health
Region. From 1961 onwards information on demographic
factors, patient characteristics and treatment is included.
The present study defined the characteristics of all patients
with a registered diagnosis of lung cancer for the period
1974-86 and concentrated on those cases with histological
confirmation. The overall aim was to relate population based
outcome data to the selected patient population included in
the clinical trial programme on Merseyside and the rest of
the United Kingdom. More specifically the intention was to
assess the impact of the introduction of new diagnostic and
therapeutic approaches on changes in the survival of sub-
groups of patients. Trends in the type of treatment employed
were examined in order to relate these to observed changes in
outcome as measured by survival time.
Methods
The Mersey Regional Cancer Registry (MRCR) computer
data base was searched for all cases of lung neoplasms
registered between 1974 and 1986 (ICD disease site code 162;
WHO (1978)). The area chosen for study was the Mersey
Regional Health Authority (MRHA), including the Isle of
Man but omitting North Wales, which was not until recently
part of the MRHA. Other peripheral Health Districts were
also excluded to avoid the effects of cross-boundary flow.
The area chosen therefore remained constant for the entire
period and comprises both sides of the River Mersey includ-
ing Liverpool and the Wirral peninsula as well as rural areas
in the Cheshire plain and Lancashire. Industrial and urban
areas make up 60% of the total and the remaining 40% is
rural. Definitive treatment was given at the same surgical
centres (Mersey Regional Adult Cardiothoracic Unit, Broad-
green Hospital and Fazakerley Hospital Thoracic Surgical
Unit) and the same regional centre for radiotherapy and
oncology (Clatterbridge Hospital). Data for Cancer Registry
use is extracted from clinical case notes and death certificates
by trained peripatetic data collectors.
Information obtained for all new cases of lung cancer
included date of diagnosis, age, sex, tumour type, treatment
and date of death. For post-mortem registrations details were
obtained retrospectively from the original clinical records.
Tumour histology was defined by standard five-digit ICD-O
code (WHO, 1978) and these were aggregated as squamous
carcinomas, small cell carcinomas (SCLC), adenocarcinomas
and undifferentiated carcinomas corresponding to the four
main WHO categories for malignant bronchial neoplasms
(WHO, 1981). Tumours not contained in any of these groups
were classed as 'other' for the purpose of this study. Detailed
analysis was confined to cases with histological confirmation
for which registration is believed to be in excess of 98%,
although all cases were included in the initial dataset.
Representative histological sections were routinely submitted
to the MRCR until 1986 for review and histological coding
was carried out by the same registry pathologist for the entire
period studied. In cases of doubt as to the histological diag-
nosis a consensus was sought with the original pathologist.
The data was processed using the commercially available
microcomputer software system, SNAP (Mercator Systems,
Bristol, UK) running on an Apricot computer. Survival was
calculated from the date of diagnosis to the date of death
according to the life table method (Peto et al., 1977). Statis-
tical comparisons of survival between subgroups were made
using the Mantel-Cox statistic provided by the BMDP pro-
gram running on the University of Copenhagen mainframe
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computer (BMDP, 1981). Deaths due to intercurrent causes
were censored.
Results
Overall results
Between 1974 and 1986 a total of 24,636 cases of lung cancer
were registered in the Mersey Region (Figure 1) of which
9,771 (40%) were histologically confirmed. Although the
total number of cases per year remained constant the
male:female ratio fell from 3.59:1 to 2.02:1 and in females
the number of histologically confirmed cases increased
steadily over the period of study from 144 in 1974 to 242 in
1986. There was a less marked decrease in the number of
male cases. The histological confirmation rate in 1974 was
43%, and rose to 51% in 1986. Males and females had
similar rates of histological confirmation.
Table I shows the number of cases within each histological
category for the entire period of study. A total of 681 (6.5%)
cases were classified as 'other' types of lung neoplasms in-
cluding 360 tumours metastatic to the lung. These 681 cases
were excluded from further analysis giving a total of 9,090
cases of primary bronchial carcinoma (WHO types I-IV)
available for detailed study.
Treatment
A total of 5,530/9,090 (61%) patients were given definitive
treatment for lung cancer (surgery, radiotherapy,
chemotherapy or combinations of these). The proportion of
patients given each modality is shown in Table II. Ninety per
cent of treated patients received single modality treatment:
surgery 40%, radiotherapy 32% and chemotherapy 18%.
Table III shows that the majority (64% overall) ofcases of
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Figure 1 Total number of registered lung neoplasms per year for
the Mersey Region. Males , females M, Total -.
Table II Treatment used in each histological category, 1974-86
WHO type S C R S±C±R C+R Total
I 1271 193 997 118 103 2682
(47) (7) (37) (5) (4) (100)
II 143 542 249 82 127 1143
(13) (47) (22) (7) (11) (100)
III 499 61 141 44 13 758
(66) (8) (19) (6) (1) (100)
IV 281 179 361 51 75 947
(30) (19) (38) (5) (8) (100)
Totals 2194 975 1748 295 318 5530
(40) (18) (32) (5) (5) (100)
S, surgery; C, chemotherapy; R, radiotherapy. I, squamous
carcinoma; II, small cell carcinoma; III, adenocarcinoma; IV,
undifferentiated carcinoma. Row percentage in parentheses.
Table III Number of patients treated per year expressed as
proportion (%) of total number of registered lung neoplasms
S±C±R C±R R Nil
1974 17 13 10 60
1975 14 12 9 65
1976 13 13 11 63
1977 12 11 13 64
1978 11 10 11 68
1979 10 11 10 69
1980 11 11 10 68
1981 9 11 14 66
1982 9 9 15 67
1983 11 10 15 64
1984 10 9 18 63
1985 10 10 20 60
1986 12 10 17 61
Mean 12 11 13 64
S, surgery; C, chemotherapy; R, radiotherapy.
lung cancer received no treatment, taking as the denominator
the number of registered cases (with or without a histological
diagnosis) each year (total 24,636). The data suggest a trend
towards an increased use of radiotherapy from 1981
onwards. The proportion of patients treated by surgery
appeared to show a slight fall over the study period. The use
ofchemotherapy altered very little in terms of the proportion
of patients treated although as is seen in a more detailed
analysis of SCLC (see below), there were major qualitative
changes in the use of this modality. It is important to note
that these figures relate to the total number of cases
registered and not only to those with histological
confirmation of WHO type I-IV tumours.
Survival by age and sex
Survival curves for five age bands are shown in Figure 2,
which includes all cases, irrespective of whether treatment
Table I Proportion of patients treated in each histological category,
1974-86
Proportion
WHO type All Treated Untreated untreated
1 4167 2682 1485 36%
(43)
II 1909 1143 766 40%
(19) 11I 1254 758 496 40%
(13)
IV 1760 947 813 46%
(18)
Subtotal 9090 5530 3560 40%
All other 681 386 295 43%
(7)
Total 9771 5916 3855 40%
(100)
Column percentages in parentheses. 1, squamous carcinoma; II,
small cell carcinoma; III, adenocarcinoma; IV, undifferentiated
carcinoma.
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Figure 2 Survival of patients by age at diagnosis: histologically
confirmed cases. Number of patients in each group: age 20-39
(0), n = 44; 40-49 (+), n = 326; 50-59 (O), n = 1,570; 60-69
(A), n = 3,280; ) 70 (x), n = 3,870.592 S.W. WATKIN et al.
was given. The data between 3 and 5 year survival time
points have been compressed to improve the resolution of the
curves in the region of the median survival time. These
curves show a clear relationship between age at diagnosis and
survival for lung cancer patients.
There was no significant difference in survival after treat-
ment between males (n = 4,106) and females (n = 1,424)
(P =0.4).
Survival by histology
Figure 3 shows the survival curves for treated cases accord-
ing to histological type. Adenocarcinoma showed the longest
survival with a median of 12 months and a 5 year survival of
22%. SCLC patients had a median survival of 6 months
following treatment with a 2 year survival of 7.5% and a 5
year survival of 3.5% (P <0.001).
Figure 4 shows similar information for untreated cases and
shows the median survival of untreated squamous carcinoma
to be 4 months compared to 2 months for SCLC. Adenocar-
cinoma and undifferentiated carcinoma showed intermediate
values. The differences were significant at P <0.001. Less
than 1% of SCLC and undifferentiated carcinoma survived 5
years without treatment and less than 5% of squamous
carcinoma and adenocarcinoma without treatment. However,
17% of patients with untreated squamous carcinoma were
Adenocarcinoma (758)
Squamous carcinoma (2682)
rUndifferentiated carcinoma (947)
Small cell carcinoma (1143)
alive at 1 year from diagnosis. Reasons for treatment not
being given were coded by Registry staff and included
advanced disease in 56% of those untreated, poor general
condition in 19%, a diagnosis at post-mortem in 10%, treat-
ment refusal in 2.5% and others 12.5%. There was no
change in survival of untreated patients in any histological
category between 1974 and 1986.
Surgery
In addition to the 2,194 out of 5,530 cases (40%) undergoing
surgery alone, a further 156 (3%) received chemotherapy and
128 (2%) received radiotherapy as well as surgical treatment.
Eleven patients (<1%) were treated by all three modalities,
giving a total of 2,489 (45%) patients treated by surgery with
or without other modalities, the survival of whom is shown
in Figure 5. Survival after surgery was similar for squamous
carcinoma and adenocarcinoma with median survival 30 and
27 months; 5 year survival 40% and 32.5%, and 10 year
survival 25% and 22.5% respectively (P >0.05). The median
survival of undifferentiated carcinoma after surgery was 11
months but the 5 year survival was 22.5%. SCLC patients
(n = 225) showed the shortest overall survival after surgery
(10% at 5 years), but in the 40% of these patients who
underwent lobectomy 5 year survival was 22.5%.
The survival of these patients was calculated for each of
the three periods 1974-77, 1978-81 and 1982-86, showing a
continuous improvement in the results after surgery for lung
cancer in the Mersey Region between 1974 and 1986. Median
survival improved from 13 to 30 months and 5 year survival
from 25 to 37.5% (Figure 6, P <0.001). The number of
patients treated by surgery in these three periods was 893,
677 and 919 respectively.
Detailed surgical staging was not recorded in the registry
data base but Figure 7 shows survival after lobectomy
(n = 1,184) or pneumonectomy (n = 1,029) for all surgical
cases in which resection was achieved, and for which the type
of operation had been recorded in the Registry. These figures
therefore differ from those shown in Table II in relation to
surgery and do not include patients undergoing exploratory
thoracotomy alone. Patients undergoing lobectomy showed
significantly longer survival than pneumonectomy patients:
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Figure 3 Survival of all treated cases according to histological
type. Numbers of patients shown in parentheses.
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Figure 4 Survival of untreated cases according to histological
type. Number of patients in each group: squamous carcinoma
(0), n = 1,485; small cell carcinoma (O), n = 766; adenocar-
cinoma (+), n = 496; undifferentiated carcinoma (A), n = 813.
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Figure 5 Survival of all cases treated by surgery according to
histological type. Number of patients shown in parentheses.
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Figure 6 Survival of surgically treated cases (all histological
types) for the periods shown. Number of patients shown in
parentheses.
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Figure 7 Survival of surgically treated cases (all histological
types) 1974-86: lobectomy versus pneumonectomy. Number of
patients shown in parentheses.
median 33 versus 16 months, 2 year survival 57.5% versus
42.5% and 5 year survival 37.5% versus 27.5% (P <0.001).
These differences were, however, less marked at 10 years.
Chemotherapy
A total of 1,460/5,530 (26%) patients received chemotherapy
either alone or in combination with another treatment
modality, of whom 741 (51%) had a histological diagnosis of
SCLC. Median survival following chemotherapy was between
4 and 6 months, with SCLC patients having the longest
median survival. The 2 year survival of patients with SCLC
treated by chemotherapy was 5% and less than 2.5% sur-
vived 5 years. There was a highly significant (P <0.001)
improvement in survival after chemotherapy for SCLC dur-
ing 1974-86 and the 2 year survival rose from 2.5% to 7.5%
over this 13 year period. Figure 8 shows the survival curve
for SCLC treated by chemotherapy for the period 1982-86
when 408 cases were treated. These changes in survival after
chemotherapy between 1974 and 1986 for SCLC were
associated with an increase in median survival from 6.5 to 8
months for all treated SCLC patients. The type of
chemotherapy used for SCLC changed from single agent
cyclophosphamide (93% of chemotherapy used until 1979) to
combination chemotherapy (82% of chemotherapy used after
1984) with other single agents constituting less than 10% of
all treatments for the entire period of study. The intravenous
route was employed in 71% of patients treated with com-
100-
bination regimes and in 27% of those receiving single agents.
The survival of SCLC patients treated by chemotherapy
using either single agent or combination chemotherapy is
shown in Figure 9. Survival in patients receiving combination
chemotherapy was superior to that of patients receiving sin-
gle agents: median 9 versus 6 months; 2 year survival 10%
versus 2.5% (P <0.001).
Radiotherapy
The proportion of patients treated by radiotherapy increased
during the period of study and radiotherapy was used in
40% of those with histological confirmation representing
13% of all patients with a Registry diagnosis of lung cancer
(Table III). The majority of patients treated by radiotherapy
were not treated by any other modality (Table II).
Overall survival following radiotherapy showed a median
survival of 6 months for SCLC, adenocarcinoma and
undifferentiated carcinoma and 8 months for squamous car-
cinoma. Between 2.5% and 5% of patients survived 5 years
following radiotherapy. There was no significant difference in
survival after radiotherapy when comparison was made
between the periods 1974-77, 1978-81 and 1982-86
(P >0.05). Patients with squamous carcinoma formed the
largest number treated by radiotherapy (1,172) and had a
median survival of 8 months for each time period. The
number of these patients in each period was 247, 303 and 622
respectively.
Overall survival
Summary survival curves for all treated cases for 1974-77,
1978-81 and 1982-86 showed a significant although small
improvement with time: median survival rose from 8 to 10
months, 2 year survival from 20 to 25% and 5 year survival
from 12.5 to 17.5% (P <0.001). These curves therefore give
an estimate of the overall impact of the various determinants
of outcome, including treatment, on survival in histologically
proven bronchial carcinoma in a large Health Region of the
United Kingdom. Figure 10 shows survival of all treated
cases, irrespective of histological type for the most recent
time period (1982-86) and Figure 11 summarises the data
for all cases of lung neoplasms in the Mersey Region for the
period 1974-86.
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Figure 8 Survival of small cell carcinoma patients treated by
chemotherapy, 1982-86 (n = 408).
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Figure 9 Survival of small cell carcinoma patients treated by
chemotherapy, 1974-86; combination chemotherapy (n = 183)
versus single agent (n = 558).
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Figure 10 Survival of all treated cases of histologically
confirmed bronchial carcinoma, 1982-86 (n = 2,518).
Discussion
Only a small proportion of patients are entered into clinical
trials and in a recent survey of 215 new cases of lung cancer
referred to McGill University, Canada, significant differences
in survival were found between patients treated 'on' or 'off
protocol (Quoix et al., 1986). This paper presents the results
of a large population based study in a Health Region of the
UK, and has demonstrated the impact of changes in treat-
ment policies, which are not brought out in reports of single
or multicentre trials, on account of their selection criteria,
relatively small numbers and referral bias (Davis et al., 1985;
Carter, 1985).
The quality of data provided by the Merseyside Registry
was very high, with very few omissions or errors in each
individual patient record. A small number of transposition
errors were identified and corrected using the computer soft-
ware and manual checking of the original Registry data file.
Survival time was specifically examined to exclude
erroneously long survival times.
The England and Wales Cancer Registration Service is
thought to hold the largest registry data set on cancers in the
world and obtains its information from Regional Registries
such as the MRCR. Completeness of data is probably over
95% and the potential effects of bias and inaccuracy have
been estimated to be less than a few per cent (Swerdlow,
1986). These factors, coupled with the effective pathological
review at the MRCR, support our contention that the data
presented in this study are accurate and consistent, and cover
virtually all cases of the disease which actually occurred.
The histological confirmation rate rose overall by 9%
between 1974 and 1986, which we feel is attributable to the
more widespread availability of fibreoptic bronchoscopy. The
number of patients in the United Kingdom undergoing
fibreoptic bronchoscopy increased over the same period from
15,000 to 40,000 per annum (Simpson et al., 1986).
The overall distribution of cell types showed the
predominance of squamous carcinoma and was in keeping
with other published series. The distribution of cell types in
the original paper of the Task Force on Lung Cancer was
squamous 46%, SCLC 17%, adenocarcinoma 24% and
undifferentiated carcinoma 12% (Mountain et al., 1974).
The increase in number of cases of lung cancer in women
shown in this study has also been confirmed by others (And-
rews et al., 1985). This has been attributed to historical
differences in smoking habits between the sexes with women
adopting heavy tobacco consumption 20 years later than
men. The fall in absolute number of cases in men did not
offset the increase in number in women, and the overall
number of cases of lung cancer occurring each year in the
Mersey Region between 1974 and 1986 did not change.
While incidence figures are not presented it is our impression
that the observed changes are real rather than due to popula-
tion shifts, and the likely continued rise in lung cancer
incidence in women (Williams, 1987) has important implica-
tions for the allocation of health care resources in those areas
with a high lung cancer incidence.
The data presented on untreated lung cancer represent the
largest available series analysed by histological type. As vir-
tually all untreated cases were shown to have died, the
long-term survival rates for treated groups do not require
adjustment for errors attributable to incorrect survival time
or failure to record death. The changes shown in survival in
the treated groups are likely to be a real effect of that
treatment, since the untreated patients in each histological
category showed numerically no change in survival over the
period of study. Assessment of the effect of treatment on
squamous cell carcinoma should take account of the 17% 1
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year survival without treatment. As expected, advanced
disease and poor performance status were the major reasons
for treatment being withheld (75% of those untreated). We
cannot comment on patients who were given active treatment
in the absence of a histological diagnosis.
Surgery
The TNM system for staging of lung cancer (Mountain,
1986) can only be employed accurately after thoracotomy. In
this retrospective survey it is not possible to obtain reliable
staging information, or to determine the reason for a treat-
ment decision, including selection criteria for modalities used.
Selection for surgery would, however, appear to be appropri-
ate and may have improved over the period of study by
greater use of flexible bronchoscopy, isotope scanning and
computerised tomography, as well as mediastinoscopy. The 5
year survival rate reported by five British surgeons in a
collective series of 8,781 patients was between 25.5 and
26.8% following surgery for bronchial carcinoma and
operative mortality was 6% for lobectomy and 12% for
pneumonectomy (Belcher, 1983), although the mortality from
the latter procedure has improved considerably during the
period of this study. The proportion of patients treated by
lobectomy has remained at about 50% since the operation
was first popularised (Belcher, 1959). Data have not been
presented for operative mortality in this study but post-
operative deaths are included in the survival curves as cancer
deaths.
Surgery for lung cancer has become increasingly safe in
recent years as a result of improved preoperative preparation
and advances in anaesthesia and intensive care facilities for
patients with lung cancer who frequently have co-existing
cardiorespiratory diseases (Johnston, 1988). Improvements in
surgical techniques, such as the introduction of stapling
devices (Kaplan et al., 1986) and bronchoplastic procedures,
are also possible reasons for the improvement shown in
survival after surgerv during the period of this study.
Histology
Overall, the data confirm previous studies which have shown
the relatively good prognosis of adenocarcinoma and
squamous carcinoma in terms of 5 year survival. However,
survival curves for all histological types show a rapid initial
fall within the first 12 months. It is clear that conventional
histology does not predict well for this early part of the
natural history: it remains to be shown whether DNA ploidy
measurement, oncoprotein or growth factor parameters may
improve this situation (Carney & De Leij, 1988) and identify
subgroups with a higher response to chemotherapy or
radiotherapy. Also, to date tumour related prognostic factors
are better established for SCLC (Osterlind & Andersen,
1986).
Treatment
The results of this study have demonstrated an improvement
over time in the survival of patients undergoing surgery for
lung cancer. The improved prognosis after chemotherapy for
SCLC would appear to justify the increasing intensity, and
hence also morbidity, of the treatments employed over the
period of study. No similar effect was seen in lung cancer
cases treated by radiotherapy, a group comprising
predominantly squamous tumours.
Demonstration of an overall improvement in survival in
population based series of common tumours has proved
elusive over the past 20-30 years, although this has been
possible for rarer tumour types including testicular cancer
(Boyle et al., 1987). There are marked Regional differences in
cancer survival data from many causes, with the poorest
figures often associated with other parameters of health, such
as infant mortality, which are also high in the North of
England (Silman & Evans, 1981).
Completeness of registration, stage at presentation, and
availability of specialist expertise and treatment facilities may
all contribute to these findings. The overall improvements in
survival shown here, while modest, strongly suggest an
association with more effective treatment for this group of
diseases.
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